FNY Partners Fund LP lifted its stake in Shire PLC (NASDAQ:SHPG) by 168.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,246 shares of the biopharmaceutical company’s stock after purchasing an additional 66,670 shares during the period. Shire makes up 2.8% of FNY Partners Fund LP’s investment portfolio, making the stock its 9th largest holding. FNY Partners Fund LP’s holdings in Shire were worth $16,270,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hartford Financial Management Inc. lifted its stake in shares of Shire by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 32 shares during the period. YorkBridge Wealth Partners LLC lifted its stake in shares of Shire by 81.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 317 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of Shire in the second quarter valued at about $171,000. Stephens Inc. AR lifted its stake in shares of Shire by 22.2% in the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 228 shares during the period. Finally, Ingalls & Snyder LLC lifted its stake in shares of Shire by 10.8% in the second quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 18.64% of the company’s stock.
A number of brokerages have issued reports on SHPG. Jefferies Group LLC restated a “hold” rating and set a $206.00 target price (down previously from $216.00) on shares of Shire in a research report on Wednesday, August 9th. Barclays PLC cut shares of Shire from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Royal Bank Of Canada restated a “buy” rating and set a $213.00 target price on shares of Shire in a research report on Monday, October 2nd. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research report on Thursday, November 16th. Finally, BidaskClub cut shares of Shire from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $212.18.
Shares of Shire PLC (NASDAQ SHPG) opened at $147.86 on Monday. The company has a market cap of $44,870.00, a PE ratio of 10.17, a PEG ratio of 0.82 and a beta of 1.60. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. The business had revenue of $3.70 billion during the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm earned $3.17 earnings per share. research analysts predict that Shire PLC will post 15 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/11/27/shire-plc-shpg-is-fny-partners-fund-lps-9th-largest-position.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.